文献速递临床免疫质量管理与危急值

亚太地区他克莫司和环孢素电化学发光免疫分析的多中心性能评估

Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region.
PubMed 文献 · Ann Lab Med · 2018-01-01

该研究在亚太地区七个中心评估罗氏Elecsys他克莫司和环孢素电化学发光免疫分析(ECLIA)的分析性能,检测重复性、再现性、准确性和批间试剂变异性,并与Architect、Dimension和Viva-E系统比较。结果显示两项目精密度良好,与他法一致性高,适用于亚太人群不同移植类型的免疫抑制剂监测。

要点

  • 他克莫司ECLIA重复性CV≤5.4%、再现性CV≤12.4%;环孢素分别为≤5.1%和≤7.3%。
  • 他克莫司ECLIA与Architect、Dimension、Viva-E比较斜率分别为1.01、1.14、0.897。
  • 环孢素ECLIA与上述系统比较斜率分别为1.04、1.04、1.09,一致性更密切。

核心结论

  • 他克莫司和环孢素ECLIA精密度优异,与其他免疫分析一致性高,适用于亚太人群不同移植类型的免疫抑制剂监测。

研究设计与样本

  • 在亚太地区七个中心(中国、韩国、马来西亚)评估罗氏Elecsys他克莫司和环孢素ECLIA的分析性能。
  • 检测重复性、再现性、准确性和批间试剂变异性,并与Architect、Dimension和Viva-E系统比较,使用不同移植类型(肾、肝、心、骨髓)患者全血样本。

主要发现

  • 他克莫司ECLIA重复性CV≤5.4%、再现性CV≤12.4%;环孢素ECLIA重复性CV≤5.1%、再现性CV≤7.3%。
  • 他克莫司ECLIA与Architect、Dimension、Viva-E比较斜率分别为1.01、1.14、0.897。
  • 环孢素ECLIA与Architect、Dimension、Viva-E比较斜率分别为1.04、1.04、1.09,一致性更密切。
  • 不同移植类型间未观察到主要差异。

关键数值与推荐

  • 他克莫司ECLIA重复性CV≤5.4%,再现性CV≤12.4%。
  • 环孢素ECLIA重复性CV≤5.1%,再现性CV≤7.3%。
  • 他克莫司ECLIA与Architect、Dimension、Viva-E比较斜率分别为1.01、1.14、0.897。
  • 环孢素ECLIA与Architect、Dimension、Viva-E比较斜率分别为1.04、1.04、1.09。

临床怎么用

  • 罗氏Elecsys他克莫司和环孢素ECLIA可用于亚太地区不同移植类型患者的免疫抑制剂血药浓度监测。
  • 临床解读结果时需注意不同免疫分析方法间存在斜率差异,尤其他克莫司与Dimension和Viva-E比较时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The immunosuppressant drugs (ISDs), tacrolimus and cyclosporine, are vital for solid organ transplant patients to prevent rejection. However, toxicity is a concern, and absorption is highly variable across patients; therefore, ISD levels need to be precisely monitored. In the Asia-Pacific (APAC) region, tacrolimus and cyclosporine concentrations are typically measured using immunoassays. The objective of this study was to assess the analytical performance of Roche Elecsystacrolimus and cyclosporinee electrochemiluminescence immunoassays (ECLIAs). METHODS: This evaluation was performed in seven centers across China, South Korea, and Malaysia. Imprecision (repeatability and reproducibility), assay accuracy, and lot-to-lot reagent variability were tested. The Elecsys ECLIAs were compared with commercially available immunoassays (Architect, Dimension, and Viva-E systems) using whole blood samples from patients with various transplant types (kidney, liver, heart, and bone marrow). RESULTS: Coefficients of variation for repeatability and reproducibility were ≤5.4% and ≤12.4%, respectively, for the tacrolimus ECLIA, and ≤5.1% and ≤7.3%, respectively, for the cyclosporine ECLIA. Method comparisons of the tacrolimus ECLIA with Architect, Dimension, and Viva-E systems yielded slope values of 1.01, 1.14, and 0.897, respectively. The cyclosporine ECLIA showed even closer agreements with the Architect, Dimension, and Viva-E systems (slope values of 1.04, 1.04, and 1.09, respectively). No major differences were observed among the different transplant types. CONCLUSIONS: The tacrolimus and cyclosporine ECLIAs demonstrated excellent precision and close agreement with other immunoassays tested. These results show that both assays are suitable for ISD monitoring in an APAC population across a range of different transplant types.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Qin X, Rui J, Xia Y, et al. Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region. Ann Lab Med. 2018. PMID: 29214751. doi:10.3343/alm.2018.38.2.85

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。